Roche Reports H1 2024 Sales Exceeding CHF 29.8 Billion with 14% Growth in China
Roche
Oncology Drug Research, Development, and Manufacturing
On July 25, Roche released its financial report for the first half of 2024. The report showed that: in the first half of the year, due to the high demand for pharmaceuticals and diagnostic products,The company's sales reached 29.848 billion Swiss francs, a year-on-year increase of 5%.If COVID-19 related products are excluded, the sales growth rate reaches 8%. As the decline in COVID-19 related sales no longer impacts the overall sales, Roche's overall business saw an accelerated sales growth of 9% in Q2.
Screenshot source: Roche financial report
In the first half of the year,Roche's pharmaceutical business sales were 22.637 billion Swiss francs, a year-on-year increase of 5%.%; excluding the impact of COVID-19, the underlying business growth rate would be 8%.
The growth of the pharmaceutical business was mainly driven by the ophthalmology bispecific drug Vabysmo (Faricimab) Increase in SalesLong, as well as the breast cancer treatment drug Phesgo (Pertuzumab/Trastuzumab/Hyaluronidase-zzxf), multiple sclerosis treatment drug Ocrevus (Ocrelizumab）、Blood Cancer Treatment Drug Polivy （Polivy) and spinal muscular atrophy drug Evrysdi (Risdiplam Oral Solution Powder) The continued growth.These five drugs combined generated total sales of 7.3 billion Swiss francs.。
Among them,Vabysmo, an ophthalmology treatment drug launched in early 2022, remains the main growth driver., in all regions (Mainly the United States) The growing demand forThe drug generated sales of 1.8 billion Swiss francs.。At the same time, due to the further slowdown in the impact of biosimilar competition, MabThera/Rituxan, Herceptin (Trastuzumab) and Avastin (Bevacizumab) Total sales decreased by 400 million Swiss francs.
Screenshot source:Roche Earnings Report PPT
By region, Roche's sales in the U.S. grew by 5%, driven by the ophthalmology treatment drug Vabysmo.Hematological Cancer Treatment DrugsPolivy、Multiple Sclerosis Treatment DrugsOcrevus andFood Allergy Medication XolaThe sales growth of ir was partially offset by the continued decline in sales of drugs whose patent protection had expired. Among them, Vabysmo achieved sales of 1.4 billion Swiss francs.
European market sales increased significantly by 10%, driven by demand for Vabysmo in France, the UK, and Germany, as well as for Phesgo, Ocrevus, and Hemlibra (Hemophilia Drugs) and the continued growth of Evrysdi.
Japan Market Sales Decreased by 28%, Mainly Due to the Supply of Ronapreve to the Government in the First Half of 2023COVID-19). Excluding this impact, Japan's sales decreased by 5% becauseThe impact of government price cuts has been offset.Strong market demand for Phesgo.
International regional sales increased by 17%, mainly due to patient demand for Perjeta, Evrysdi, Phesgo, and Tecentriq (Cancer Immunotherapy) The demand growth. Among them,Sales in the Chinese market increased by 14%, the main driver is Perjeta (Pertuzumab,Breast Cancer）、 Alecensa（Alectinib,Lung Cancer）、 Avastin（Bevacizumab,Liver Cancer）、Xofluza（Baloxavir Marboxil,Anti-Influenza Medications) and Polivy（Polivy, Hematologic Cancer）。
In addition, Roche also disclosed updates on the company's R&D pipeline in its financial report. Currently, Roche is primarily focusing on high-impact projects, since...Since Q2 2023,The company has terminated 25% of its new molecular entity pipeline.
